Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Refractory Panic Disorder
NCT00118417Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 1999
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in panic disorder comparing Sertraline + Placebo -> Sertraline + CBT with Sertraline High Dose -> Sertraline + Clonazepam (2 arms). Primary endpoints: Change in Panic Disorder Symptoms, Phase 1 at 6 weeks, Change in Panic Disorder Symptoms, Phase 2 at 12 weeks and 1 more. Started Mar 1999; status: completed.
02
Drugs
sertralineclonazepam
03
Conditions
panic disorder
Beyond the preview
Go deeper on NCT00118417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118417.